239 related articles for article (PubMed ID: 25043209)
21. Interstitial shadow on chest CT is associated with the onset of interstitial lung disease caused by chemotherapeutic drugs.
Niho S; Goto K; Yoh K; Kim YH; Ohmatsu H; Kubota K; Saijo N; Nishiwaki Y
Jpn J Clin Oncol; 2006 May; 36(5):269-73. PubMed ID: 16702163
[TBL] [Abstract][Full Text] [Related]
22. Both gefitinib and erlotinib induced drug-related interstitial lung disease in a patient with pulmonary adenocarcinoma.
Wang KF; Chang CY; Chang SC; Liu YC; Yuan MK; Yang YH
J Chin Med Assoc; 2013 Mar; 76(3):173-5. PubMed ID: 23497972
[TBL] [Abstract][Full Text] [Related]
23. [Four cases of interstitial lung disease induced by erlotinib and a review of the literatures].
Wu X; Gao G; Ren S; Zhou C
Zhongguo Fei Ai Za Zhi; 2012 Aug; 15(8):494-8. PubMed ID: 22901999
[TBL] [Abstract][Full Text] [Related]
24. Risk of fatal pulmonary events in patients with advanced non-small-cell lung cancer treated with EGF receptor tyrosine kinase inhibitors: a comparative meta-analysis.
Abdel-Rahman O; Elhalawani H
Future Oncol; 2015; 11(7):1109-22. PubMed ID: 25804125
[TBL] [Abstract][Full Text] [Related]
25. High exposure to erlotinib and severe drug-induced interstitial lung disease in patients with non-small-cell lung cancer.
Fujita K; Hirose T; Kusumoto S; Sugiyama T; Shirai T; Nakashima M; Akiyama Y; Sasaki Y
Lung Cancer; 2014 Oct; 86(1):113-4. PubMed ID: 25123334
[No Abstract] [Full Text] [Related]
26. Successful treatment with erlotinib after gefitinib-induced interstitial lung disease: a case report and literature review.
Koma Y; Matsuoka H; Yoshimatsu H; Suzuki Y
Int J Clin Pharmacol Ther; 2012 Oct; 50(10):760-4. PubMed ID: 22853866
[TBL] [Abstract][Full Text] [Related]
27. Interstitial lung disease in patients with non-small-cell lung cancer treated with epidermal growth factor receptor inhibitors.
Tsuboi M; Le Chevalier T
Med Oncol; 2006; 23(2):161-70. PubMed ID: 16720916
[TBL] [Abstract][Full Text] [Related]
28. [Fatal interstitial lung disease associated with erlotinib use].
Eshuis M; Ahsmann EJ; van Egmond NH
Ned Tijdschr Geneeskd; 2013; 157(7):A5519. PubMed ID: 23406641
[TBL] [Abstract][Full Text] [Related]
29. Low forced vital capacity predicts cytotoxic chemotherapy-associated acute exacerbation of interstitial lung disease in patients with lung cancer.
Enomoto Y; Inui N; Kato T; Baba T; Karayama M; Nakamura Y; Ogura T; Suda T
Lung Cancer; 2016 Jun; 96():63-7. PubMed ID: 27133752
[TBL] [Abstract][Full Text] [Related]
30. Gefitinib-Induced Interstitial Lung Disease in Korean Lung Cancer Patients.
Beom SH; Kim DW; Sim SH; Keam B; Park JH; Lee JO; Kim TM; Lee SH; Heo DS
Cancer Res Treat; 2016 Jan; 48(1):88-97. PubMed ID: 25761482
[TBL] [Abstract][Full Text] [Related]
31. Impact of preexisting pulmonary fibrosis detected on chest radiograph and CT on the development of gefitinib-related interstitial lung disease.
Naito Y; Tsuchiya S; Ishihara S; Minato K; Shitara Y; Takise A; Suga T; Mogi A; Yamabe K; Saito R
Am J Clin Oncol; 2008 Aug; 31(4):340-4. PubMed ID: 18845992
[TBL] [Abstract][Full Text] [Related]
32. Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer.
Takeda M; Okamoto I; Nakagawa K
Lung Cancer; 2015 Apr; 88(1):74-9. PubMed ID: 25704957
[TBL] [Abstract][Full Text] [Related]
33. Gefitinib-related interstitial lung disease in Taiwanese patients with non-small-cell lung cancer.
Chang SC; Chang CY; Chang SJ; Yuan MK; Lai YC; Liu YC; Chen CY; Kuo LC; Yu CJ
Clin Lung Cancer; 2013 Jan; 14(1):55-61. PubMed ID: 22607779
[TBL] [Abstract][Full Text] [Related]
34. Recurrent gefitinib-induced interstitial lung disease.
Suzuki M; Asahina H; Konishi J; Yamazaki K; Nishimura M
Intern Med; 2008; 47(6):533-6. PubMed ID: 18344641
[TBL] [Abstract][Full Text] [Related]
35. Drug-induced interstitial lung disease in tyrosine kinase inhibitor therapy for non-small cell lung cancer: a review on current insight.
Min JH; Lee HY; Lim H; Ahn MJ; Park K; Chung MP; Lee KS
Cancer Chemother Pharmacol; 2011 Nov; 68(5):1099-109. PubMed ID: 21913033
[TBL] [Abstract][Full Text] [Related]
36. Erlotinib or gefitinib for non-small-cell lung cancer.
Kaye FJ; Jantz MA; Dallas J
N Engl J Med; 2011 Jun; 364(24):2367; author reply 2368. PubMed ID: 21675909
[No Abstract] [Full Text] [Related]
37. Crizotinib Associated with Ground-Glass Opacity Predominant Pattern Interstitial Lung Disease: A Retrospective Observational Cohort Study with a Systematic Literature Review.
Créquit P; Wislez M; Fleury Feith J; Rozensztajn N; Jabot L; Friard S; Lavole A; Gounant V; Fillon J; Antoine M; Cadranel J
J Thorac Oncol; 2015 Aug; 10(8):1148-55. PubMed ID: 26200268
[TBL] [Abstract][Full Text] [Related]
38. Pre-existing interstitial lung abnormalities are risk factors for immune checkpoint inhibitor-induced interstitial lung disease in non-small cell lung cancer.
Nakanishi Y; Masuda T; Yamaguchi K; Sakamoto S; Horimasu Y; Nakashima T; Miyamoto S; Tsutani Y; Iwamoto H; Fujitaka K; Miyata Y; Hamada H; Okada M; Hattori N
Respir Investig; 2019 Sep; 57(5):451-459. PubMed ID: 31248832
[TBL] [Abstract][Full Text] [Related]
39. Erlotinib-associated interstitial lung disease in advanced pancreatic carcinoma: a case report and literature review.
Macerelli M; Mazzer M; Foltran L; Cardellino GG; Aprile G
Tumori; 2015 Jul; 101(4):e122-7. PubMed ID: 25953445
[TBL] [Abstract][Full Text] [Related]
40. Erlotinib for pretreated squamous cell carcinoma of the lung in Japanese patients.
Hata A; Katakami N; Kunimasa K; Yoshioka H; Fujita S; Kaji R; Tachikawa R; Tomii K; Imai Y; Iwasaku M; Ishida T
Jpn J Clin Oncol; 2011 Dec; 41(12):1366-72. PubMed ID: 22058419
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
